Intersection of Immune and Oncometabolic Pathways Drives Cancer Hyperprogression During Immunotherapy

Authors

Gaopeng Li
Jae Eun Choi
Ilona Kryczek
Yilun Sun
Peng Liao
Shasha Li
Shuang Wei
Sara Grove
Linda Vatan
Reagan Nelson
Grace Schaefer
Steven G Allen
Kamya Sankar
Leslie A Fecher
Mishal Mendiratta-Lala
Timothy L Frankel
Angel Qin
Jessica J Waninger
Alangoya Tezel
Ajjai Alva
Christopher D Lao
Nithya Ramnath
Marcin Cieslik
Paul W Harms
Michael D Green
Arul M Chinnaiyan
Weiping Zou

Publication Date

2-13-2023

Journal

Cancer Cell

Abstract

Immune checkpoint blockade (ICB) can produce durable responses against cancer. We and others have found that a subset of patients experiences paradoxical rapid cancer progression during immunotherapy. It is poorly understood how tumors can accelerate their progression during ICB. In some preclinical models, ICB causes hyperprogressive disease (HPD). While immune exclusion drives resistance to ICB, counterintuitively, patients with HPD and complete response (CR) following ICB manifest comparable levels of tumor-infiltrating CD8

Keywords

Animals, beta Catenin, CD8-Positive T-Lymphocytes, Fibroblast Growth Factor 2, Neoplasms, Disease Progression, Interferon-gamma, Immunotherapy

Comments

PMID: 36638784

Supplementary Material

DOI

10.1016/j.ccell.2022.12.008

PMID

36638784

PMCID

PMC10286807

PubMedCentral® Posted Date

February 2024

PubMedCentral® Full Text Version

Author MSS

Published Open-Access

yes